Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer

Cancer

Volumn 116, Issue 19, 2010, Pages 4502-4512

  Becker, Markus ^a   Szarvas, Tibor ^a   Wittschier, Markus ^a   Vom Dorp, Frank ^a   Tötsch, Martin ^a   Schmid, Kurt Werner ^a   Rübben, Herbert ^a   Ergün, Süleyman ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Biomarker; Bladder cancer; Plasminogen activator inhibitor type 1; Prognosis; Survival

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; BLOOD; CARCINOMA, TRANSITIONAL CELL; METABOLISM; MIDDLE AGED; MORTALITY; URINARY BLADDER NEOPLASMS; URINE;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77957569788     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25326     Document Type: Article

References (31)

1. Gontero P, Banisadr S, Frea B, Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol. 2004;46:296-311.
2. Becker M, Tilki D, Szarvas T, Rubben H, Ergun S. Urine-based markers of angiogenesis in bladder cancer. Urologe A. 2009;48:609-614.
3. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997;78:285-296.
4. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130-135.
5. Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol. 1995;8:291-312.
6. Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004;91:450-456. (Pubitemid 38396866)
7. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-771.
8. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer. 1997;71:116-122.
9. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-928.
10. Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 B breast cancer cells. J Biol Chem. 2002;277:40950-40957.
11. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer. 2000;82:1702-1708.
12. Lademann UA, Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost. 2008;100:1041-1046.
13. Span PN, Witjes JA, Grebenchtchikov N, et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int. 2008;102:177-182.
14. Droller MJ. Markers in bladder cancer. Issues to consider. J Urol.1998;160:2009-2010.
15. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163:60-61.
16. Eble JN, Epstein JI, Sesterhenn I. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press;2004:89-158.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC[T]) methods. Methods. 2001;25:402-408.
18. Ergun S, Kilik N, Ziegeler G, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell. 2000;5:311-320.
19. Bashar H, Urano T, Fukuta K, et al. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int. 1994;52:4-8.
20. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001;12:51-58.
21. Palmirotta R, Ferroni P, Savonarola A, et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res. 2009;124:403-408.
22. Torii K, Kimura H, Li X, et al. Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples. Rinsho Byori. 2004;52:506-512.
23. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2007;36:184-194.
24. Sternlicht MD, Dunning AM, Moore DH, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006;15:2107-2114.
25. Kuhn W, Schmalfeldt B, Reuning U, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIC. Br J Cancer. 1999;79:1746-1751.
26. Chen SC, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol. 2009;181:336-342.
27. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 1996;77:1079-1088.
28. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;6:8319-8326.
29. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986-6990.
30. Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 2002;16:147-154.
31. Frandsen TL, Holst-Hansen C, Nielsen BS, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res. 2001;61:532-537.